← Back to Search

Vaccine

Moderna mRNA-1273 vaccine for Healthy Subjects

Phase 2
Waitlist Available
Research Sponsored by Regeneron Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 401 days
Awards & highlights

Study Summary

This trial is studying if a combination of two drugs, REGN10933 and REGN10987, can help the body create immunity against the SARS-CoV-2 virus.

Eligible Conditions
  • Healthy Subjects
  • Chronic Illness

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 401 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 401 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
50% inhibitory dilution (ID50) titers of vaccine-induced neutralizing antibodies to the SARS-CoV-2 S protein
Secondary outcome measures
Antibodies, Blocking
Absolute values in concentrations of vaccine-induced antibodies to SARS-CoV-2 antigens over time
Change from baseline in concentrations of vaccine-induced antibodies to SARS-CoV-2 antigens over time
+12 more

Trial Design

12Treatment groups
Experimental Treatment
Group I: Wave 4 Vaccine onlyExperimental Treatment1 Intervention
Group II: Wave 4 Dose 1Experimental Treatment2 Interventions
Group III: Wave 3 Vaccine onlyExperimental Treatment1 Intervention
Group IV: Wave 3 Dose 2Experimental Treatment2 Interventions
Group V: Wave 3 Dose 1Experimental Treatment2 Interventions
Group VI: Wave 2 Vaccine onlyExperimental Treatment1 Intervention
Group VII: Wave 2 Dose 2Experimental Treatment2 Interventions
Group VIII: Wave 2 Dose 1Experimental Treatment2 Interventions
Group IX: Wave 1 Vaccine onlyExperimental Treatment1 Intervention
Group X: Wave 1 Dose 3Experimental Treatment2 Interventions
Group XI: Wave 1 Dose 2Experimental Treatment2 Interventions
Group XII: Wave 1 Dose 1Experimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
casirivimab+imdevimab
2021
Completed Phase 2
~300
Moderna mRNA-1273 vaccine
2021
Completed Phase 2
~300

Find a Location

Who is running the clinical trial?

Regeneron PharmaceuticalsLead Sponsor
617 Previous Clinical Trials
379,910 Total Patients Enrolled
Clinical Trial ManagementStudy DirectorRegeneron Pharmaceuticals
260 Previous Clinical Trials
250,747 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Kentucky
Florida
How old are they?
18 - 65
What site did they apply to?
Regeneron Research Site
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Typically responds via
Phone Call
Email
Most responsive sites:
  1. Regeneron Research Site: < 48 hours
Average response time
  • < 2 Days
Recent research and studies
clinicaltrials.govStudy
COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers
2021. "COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04852978.
~75 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top